{"analyses":[{"groupDescription":"The p-value was the probability that the number of responders is greater than or equal to the observed number, although the true response rate was smaller or equal to 60%. Null hypothesis (H0): p-value \\<=0.6; alternate hypothesis (H1): p-value \\>0.6.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false},{"groupDescription":"The p-value was the probability that the number of responders is greater than or equal to the observed number, although the true response rate was smaller or equal to 60%. Null hypothesis (H0): p-value \\<=0.6; alternate hypothesis (H1): p-value \\>0.6.","groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"89.13","upperLimit":"97.28","value":"94.12"},{"groupId":"OG001","lowerLimit":"88.38","upperLimit":"96.84","value":"93.51"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"description":"Hb response was an observed increase in Hb greater than or equal to (\\>=) 1.0 gram per deciliter (g/dL) from baseline and an Hb concentration \\>= 10.0 g/dL before the end of the study without red blood cells (RBC) transfusion before response.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Mircera (Methoxy polyethylene glycol-epoetin beta), administered SC at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.","id":"OG000","title":"Mircera"},{"description":"Participants received darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.","id":"OG001","title":"Darbepoetin Alfa"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat (ITT) population included all randomized participants. Participants were analyzed according to the study treatment assigned.","reportingStatus":"POSTED","timeFrame":"Baseline up to Week 28","title":"Percentage of Participants With Hemoglobin (Hb) Response","type":"PRIMARY","unitOfMeasure":"percentage of participants"}